State Street: Travere Therapeutics TVTX Historial de posiciones en acciones
Comprado
Mantenidas
Vendido
| Trimestre | Valor de mercado | Estado | Acciones |
Cambio en la posición | Valor operado | Peso en el portafolio | Puesto en el portafolio | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | USD 258 M | Compra |
4,387,309
+131,085
| +3% | +USD 8 M | 0.01% | 851 |
|
|
2026
Q2 | USD 242 M | Venta |
4,256,224
-703,764
| -14% | -USD 31.2 M | 0.01% | 933 |
|
|
2026
Q1 | USD 147 M | Compra |
4,959,988
+203,322
| +4% | +USD 6.08 M | 0.01% | 1140 |
|
|
2025
Q4 | USD 182 M | Compra |
4,756,666
+1,538,827
| +48% | +USD 50 M | 0.01% | 993 |
|
|
2025
Q3 | USD 76.9 M | Venta |
3,217,839
-265,337
| -8% | -USD 4.99 M | ﹤0.01% | 1501 |
|
|
2025
Q2 | USD 51.6 M | Venta |
3,483,176
-163,539
| -4% | -USD 2.71 M | ﹤0.01% | 1660 |
|
|
2025
Q1 | USD 65.3 M | Venta |
3,646,715
-120,520
| -3% | -USD 2.45 M | ﹤0.01% | 1504 |
|
|
2024
Q4 | USD 65.6 M | Compra |
3,767,235
+1,030,539
| +38% | +USD 18.2 M | ﹤0.01% | 1583 |
|
|
2024
Q3 | USD 38.3 M | Venta |
2,736,696
-773,981
| -22% | -USD 8.06 M | ﹤0.01% | 1839 |
|
|
2024
Q2 | USD 28.9 M | Venta |
3,510,677
-3,098,019
| -47% | -USD 20.9 M | ﹤0.01% | 1961 |
|
|
2024
Q1 | USD 51 M | Compra |
6,608,696
+1,256,351
| +23% | +USD 10.6 M | ﹤0.01% | 1720 |
|
|
2023
Q4 | USD 48.1 M | Compra |
5,352,345
+957,088
| +22% | +USD 6.97 M | ﹤0.01% | 1723 |
|
|
2023
Q3 | USD 39.3 M | Venta |
4,395,257
-1,337,379
| -23% | -USD 18.9 M | ﹤0.01% | 1777 |
|
|
2023
Q2 | USD 88.1 M | Compra |
5,732,636
+1,364,759
| +31% | +USD 24.8 M | ﹤0.01% | 1310 |
|
|
2023
Q1 | USD 98.2 M | Compra |
4,367,877
+143,853
| +3% | +USD 3.06 M | 0.01% | 1199 |
|
|
2022
Q4 | USD 88.8 M | Compra |
4,224,024
+810,609
| +24% | +USD 17.2 M | 0.01% | 1235 |
|
|
2022
Q3 | USD 84.1 M | Venta |
3,413,415
-193,750
| -5% | -USD 5.01 M | 0.01% | 1234 |
|
|
2022
Q2 | USD 87.4 M | Compra |
3,607,165
+647,804
| +22% | +USD 16.3 M | 0.01% | 1257 |
|
|
2022
Q1 | USD 76.3 M | Compra |
2,959,361
+72,284
| +3% | +USD 1.92 M | ﹤0.01% | 1485 |
|
|
2021
Q4 | USD 89.6 M | Compra |
2,887,077
+104,754
| +4% | +USD 2.95 M | ﹤0.01% | 1384 |
|
|
2021
Q3 | USD 67.5 M | Venta |
2,782,323
-671,536
| -19% | -USD 12.3 M | ﹤0.01% | 1583 |
|
|
2021
Q2 | USD 50.4 M | Compra |
3,453,859
+1,014,332
| +42% | +USD 20 M | ﹤0.01% | 1843 |
|
|
2021
Q1 | USD 60.9 M | Compra |
+2,439,527
| Nuevas | +USD 67.4 M | ﹤0.01% | 1592 |
|
|
2020
Q4 | – | Venta |
-1,920,415
| Cerradas | -USD 35.5 M | – | 3907 |
|
|
2020
Q3 | USD 35.5 M | Compra |
1,920,415
+82,309
| +4% | +USD 1.6 M | ﹤0.01% | 1692 |
|
|
2020
Q2 | USD 37.5 M | Compra |
1,838,106
+112,534
| +7% | +USD 1.79 M | ﹤0.01% | 1623 |
|
|
2020
Q1 | USD 25.2 M | Venta |
1,725,572
-11,829
| -0.7% | -USD 178 k | ﹤0.01% | 1698 |
|
|
2019
Q4 | USD 24.7 M | Venta |
1,737,401
-415,022
| -19% | -USD 5.3 M | ﹤0.01% | 1997 |
|
|
2019
Q3 | USD 24.9 M | Compra |
2,152,423
+535,168
| +33% | +USD 8.84 M | ﹤0.01% | 1919 |
|
|
2019
Q2 | USD 32.5 M | Compra |
1,617,255
+19,598
| +1% | +USD 387 k | ﹤0.01% | 1765 |
|
|
2019
Q1 | USD 36.2 M | Compra |
1,597,657
+180,708
| +13% | +USD 3.99 M | ﹤0.01% | 1645 |
|
|
2018
Q4 | USD 32.1 M | Venta |
1,416,949
-17,860
| -1% | -USD 444 k | ﹤0.01% | 1645 |
|
|
2018
Q3 | USD 41.2 M | Venta |
1,434,809
-16,603
| -1% | -USD 475 k | ﹤0.01% | 1687 |
|
|
2018
Q2 | USD 39.6 M | Compra |
1,451,412
+189,959
| +15% | +USD 5.06 M | ﹤0.01% | 1641 |
|
|
2018
Q1 | USD 28.2 M | Compra |
1,261,453
+17,430
| +1% | +USD 415 k | ﹤0.01% | 1807 |
|
|
2017
Q4 | USD 26.2 M | Compra |
1,244,023
+77,285
| +7% | +USD 1.77 M | ﹤0.01% | 1865 |
|
|
2017
Q3 | USD 29 M | Venta |
1,166,738
-21,814
| -2% | -USD 480 k | ﹤0.01% | 1751 |
|
|
2017
Q2 | USD 23 M | Venta |
1,188,552
-15,571
| -1% | -USD 282 k | ﹤0.01% | 1882 |
|
|
2017
Q1 | USD 22.2 M | Compra |
1,204,123
+2,405
| +0.2% | +USD 47 k | ﹤0.01% | 1866 |
|
|
2016
Q4 | USD 22.8 M | Compra |
1,201,718
+151,543
| +14% | +USD 3.1 M | ﹤0.01% | 1807 |
|
|
2016
Q3 | USD 23.5 M | Compra |
1,050,175
+74,752
| +8% | +USD 1.42 M | ﹤0.01% | 1676 |
|
|
2016
Q2 | USD 17.4 M | Venta |
975,423
-154,963
| -14% | -USD 2.51 M | ﹤0.01% | 1853 |
|
|
2016
Q1 | USD 15.4 M | Venta |
1,130,386
-103,221
| -8% | -USD 1.57 M | ﹤0.01% | 1901 |
|
|
2015
Q4 | USD 23.8 M | Venta |
1,233,607
-165,379
| -12% | -USD 3.3 M | ﹤0.01% | 1596 |
|
|
2015
Q3 | USD 28.3 M | Compra |
1,398,986
+82,281
| +6% | +USD 2.44 M | ﹤0.01% | 1511 |
|
|
2015
Q2 | USD 43.6 M | Compra |
1,316,705
+929,217
| +240% | +USD 25.4 M | ﹤0.01% | 1355 |
|
|
2015
Q1 | USD 9.28 M | Compra |
387,488
+95,742
| +33% | +USD 1.46 M | ﹤0.01% | 2251 |
|
|
2014
Q4 | USD 3.57 M | Compra |
291,746
+10,648
| +4% | +USD 110 k | ﹤0.01% | 2749 |
|
|
2014
Q3 | USD 2.54 M | Compra |
281,098
+22,708
| +9% | +USD 267 k | ﹤0.01% | 2888 |
|
|
2014
Q2 | USD 3.04 M | Compra |
258,390
+76,114
| +42% | +USD 1.03 M | ﹤0.01% | 2860 |
|
|
2014
Q1 | USD 3.88 M | Compra |
+182,276
| Nuevas | +USD 2.8 M | ﹤0.01% | 2723 |
|
Otros fondos que tienen TVTX en su portafolio
Posición de State Street en TVTX: resumen de T3 2026
State Street aumentó su participación en Travere Therapeutics (TVTX) en 3.1% durante T3 2026, al comprar aproximadamente USD 8 M y elevar la posición a 4,387,309 acciones con un valor de USD 258 M. La posición representa 0.01% del portafolio y ocupa el puesto #851.
State Street reportó por primera vez una posición en TVTX en T1 2014 y desde entonces la ha mantenido en 50 trimestres. Al cierre de T3 2026, 345 fondos que sigue Wall St. Rank mantienen una posición en TVTX.
- Al cierre de T3 2026, State Street tenía 4,387,309 acciones de Travere Therapeutics con un valor de USD 258 M.
- State Street compró 131,085 acciones de Travere Therapeutics en T3 2026, por un monto estimado de USD 8 M.
- Travere Therapeutics representó el 0.01% del portafolio de State Street en T3 2026 y fue su posición número 851.
- State Street reportó por primera vez una posición en Travere Therapeutics en T1 2014 y desde entonces la ha mantenido en 50 trimestres.
- Al cierre de T3 2026, 345 fondos que sigue Wall St. Rank tenían Travere Therapeutics en su portafolio.
Según el informe 13F de State Street correspondiente a T3 2026, presentado el 12 nov 2026.